BACKGROUND:Vitamin A has immunomodulatory properties and may regulate the transcription of genes involved in remyelination. OBJECTIVE: To investigate the association between retinol and disease activity in multiple sclerosis (MS). METHODS: Cohort study of 88 relapsing-remitting MS patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS study), followed prospectively for 24 months with repeated assessments of serum-retinol and magnetic resonance imaging (MRI). All patients were initiated on interferon β-1a after month 6. RESULTS: Each 1 µmol/L increase in serum-retinol reduced the odds (95% confidence interval) for new T1 gadolinium enhanced (Gd(+)) lesions by 49 (8-70)%, new T2 lesions by 42 (2-66)%, and combined unique activity (CUA) by 46 (3-68)% in simultaneous MRI scans, and 63 (25-82)% for new T1Gd(+) lesions, 49 (3-73)% for new T2 lesions and 43 (12-71)% for CUA the subsequent month. Serum-retinol also predicted new T1Gd(+) and T2 lesions six months ahead. The associations were not affected by HLA-DRB1*15, or serum levels of 25-hydroxyvitamin D, eicosapentaenoic acid or docosahexaenoic acid. CONCLUSION:Serum retinol is inversely associated with simultaneous and subsequent MRI outcomes in RRMS.
RCT Entities:
BACKGROUND:Vitamin A has immunomodulatory properties and may regulate the transcription of genes involved in remyelination. OBJECTIVE: To investigate the association between retinol and disease activity in multiple sclerosis (MS). METHODS: Cohort study of 88 relapsing-remitting MS patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS study), followed prospectively for 24 months with repeated assessments of serum-retinol and magnetic resonance imaging (MRI). All patients were initiated on interferon β-1a after month 6. RESULTS: Each 1 µmol/L increase in serum-retinol reduced the odds (95% confidence interval) for new T1 gadolinium enhanced (Gd(+)) lesions by 49 (8-70)%, new T2 lesions by 42 (2-66)%, and combined unique activity (CUA) by 46 (3-68)% in simultaneous MRI scans, and 63 (25-82)% for new T1Gd(+) lesions, 49 (3-73)% for new T2 lesions and 43 (12-71)% for CUA the subsequent month. Serum-retinol also predicted new T1Gd(+) and T2 lesions six months ahead. The associations were not affected by HLA-DRB1*15, or serum levels of 25-hydroxyvitamin D, eicosapentaenoic acid or docosahexaenoic acid. CONCLUSION: Serum retinol is inversely associated with simultaneous and subsequent MRI outcomes in RRMS.
Authors: Kareem L Graham; Bonnie J Werner; Kimberly M Moyer; Alycia K Patton; Charles R Krois; Hong Sik Yoo; Maria Tverskoy; Melissa LaJevic; Joseph L Napoli; Raymond A Sobel; Brian A Zabel; Eugene C Butcher Journal: Proc Natl Acad Sci U S A Date: 2019-02-04 Impact factor: 11.205
Authors: Ali Akbar Saboor-Yaraghi; Mohammad Hossein Harirchian; Niyaz Mohammadzadeh Honarvar; Sama Bitarafan; Mina Abdolahi; Feridoun Siassi; Eisa Salehi; Mohammad Ali Sahraian; Mohammad Reza Eshraghian; Tina Roostaei; Fariba Koohdani Journal: J Mol Neurosci Date: 2015-05-19 Impact factor: 3.444
Authors: John Michael S Sanchez; Ana Beatriz DePaula-Silva; Jane E Libbey; Robert S Fujinami Journal: Clin Immunol Date: 2020-03-07 Impact factor: 3.969
Authors: Kristin I Løken-Amsrud; Kjell-Morten Myhr; Søren J Bakke; Antonie G Beiske; Kristian S Bjerve; Bård T Bjørnarå; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jūratė Šaltytė Benth; Øivind Torkildsen; Stig Wergeland; Trygve Holmøy Journal: PLoS One Date: 2013-01-22 Impact factor: 3.240